A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Analgesic Efficacy, Safety and Tolerability of VPX638 Administered Topically on a Single Study Occasion, to Patients with Painful Wounds
Latest Information Update: 05 Nov 2019
Price :
$35 *
At a glance
- Drugs VPX-638 (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Vapogenix
- 29 Oct 2019 According to a Vapogenix media release, data from the Phase II trial of VPX638 will inform the design of Phase IIb/III studies.
- 29 Oct 2019 According to a Vapogenix Primary endpoint has not been met.
- 29 Oct 2019 Results presented in a Vapogenix Media Release.